beta-blockers in STEMI

  Perspective – medication in acute coronary syndromes. Many of the study endpoints in ischaemic heart disease studies are so-called composite endpoints, meaning that the statisticians analyse a number derived from a combination of adverse events – e.g. myocardial infarction,… Read More »Ischaemic heart disease treatment perspectives